AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
DDD

3D Systems Corporation Common Stock (DDD) fair value

Technology · Computer Hardware · NYSE · United States
$3.04-0.33%
Market cap $507MNext earnings 2026-11-03Updated Oct 20, 2026
Add earnings to calendarGoogle
Our verdict
Trades 7% above our fair value
Price
$3.04
Model fair valueConfidence: medium
$2.85
Only one of our models could value this stock with confidence, so use it as a guide.
Not used by alerts or posts.
Valued as a cyclical company: EV/EBITDA comparison, Discounted cash flow, and Graham number.
ACCE opinion3D Systems Corporation Common Stock (DDD)
Fair value (2 models)
Not available
ACCE price target
$2.73
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $3.04 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
39
out of 100
Analysts
50% buy
4 covering
P/E
0.0x
forward 22.5x
1-year return
-1.3%
Dividend yield
0.00%

3D Systems Corporation Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

3D Systems sells industrial and dental 3D printers, the materials and software that run them, and printed parts and services for aerospace, medical and automotive customers, with dental aligner and surgical guide production a notable part of the medical mix. The structural argument is that its installed base and materials revenue are sticky, and that the dental and medical end markets are less cyclical than general prototyping. Revenue is roughly flat (down 0.3%), operating margin is still negative at -11.3% against a 33.8% gross margin, and ROE is -21.3%, so the business has not yet converted its gross margin into profit. The forward P/E of 22.5 implies the market expects earnings to recover, which makes the next few quarters of cost reduction and margin progression the test to watch. At a 492M market cap with a score of 43/100 and no index membership, this is a turnaround candidate that needs evidence of operating leverage before it merits a deeper look.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
  • severe
    Cash burn exceeds market cap
    Free cash flow was -$97.8M against a $459M market cap, with operating margin at -11.3% and net margin at -14.1%. The business is consuming cash faster than it earns it.
  • high
    Revenue shrinking over five years
    Revenue has compounded at -7.0% over five years and is down 0.3% year on year. Gross margin of 33.8% does not offset the lack of top-line growth.
  • high
    Heavy short interest
    Short interest stands at 27.3% of the float. That is a large bet against the shares, and it can amplify volatility in either direction.
  • moderate
    Score fell sharply in 90 days
    The ACCE score dropped 13 points, from 52 to 39, over the last 90 days. Quality (35) and valuation (45) are the weakest components.

AI research notes

AI-assisted·How I use AIWritten Oct 19, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Analysts are fairly constructive, with half of those covering the stock rating it Buy or Strong Buy.
  • The most recent quarter beat expectations, with earnings per share of -0.06 against -0.12 expected.
  • The share count fell 4.7% last fiscal year, so each remaining share holds a slightly larger claim on the business.
Why it could disappoint
  • Free cash flow over the last twelve months was negative $98M, meaning the business is consuming cash rather than generating it.
  • Revenue has shrunk on average by 7.0% a year over five years, and the latest year-over-year change was -0.3%.
  • The net margin of -14.1% and return on equity of -21.3% show the company is still losing money on the capital invested in it.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 3, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where DDD's valuation models land
Price
$3.04
Model fair valueConfidence: medium
$2.85
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
Graham number
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Mixed50% buy · 4 covering analysts
● Strong buy 2● Buy 0● Hold 2● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+10.1%
1 month
-13.4%
3 months
+18.3%
6 months
+34.5%
YTD
+71.8%
1 year
-1.3%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
15 Oct 2026, 00:00 CESTACCE price target$2.73first publication$3.19
9 Oct 2026, 00:00 CESTFair value$2.07$2.17$3.41
6 Oct 2026, 00:00 CESTFair value$2.17$2.14$3.78
29 Sept 2026, 00:00 CESTFair value$2.14$2.11$3.57
26 Sept 2026, 00:00 CESTFair value$2.11$2.16$3.43
21 Sept 2026, 00:00 CESTFair value$2.16$2.24$3.63
19 Sept 2026, 00:00 CESTFair value$2.24$2.06$3.54
16 Sept 2026, 00:00 CESTFair value$2.06$2.14$3.21
8 Sept 2026, 00:00 CESTFair value$2.14$2.09$3.46
23 Aug 2026, 00:00 CESTFair value$2.09$2.14$3.18

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full DDD page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth7Value45Quality35Momentum70Total39
Valuation
Trailing P/E
0.0x
Forward P/E
22.5x
PEG
0.85
P/B
2.13x
EV / Revenue
1.5x
Book value/sh
$1.65
Enterprise value
$597M
Profitability
ROE
-21.3%
FCF yield
-19.49%
ROIC
6.1%
Health and risk
Debt / equity
0.66
Dividend yield
0.00%
Beta
2.77

Price

-2.9% · 1Y

Ask anything about DDD

Answered from 3D Systems Corporation Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 0.0x0.0xhigh 73.9x
ROEbetter than 17% of peers
low -25%-21%high 24%
Div yieldbetter than 83% of peers
low 0.0%0.0%high 3.5%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
DDD 3D Systems Corporation Common Stock$3.04----21.3%3539
NNDM Nano Dimension Ltd. American Depositary Shares$1.38----24.5%3932
SSYS Stratasys Ltd. Ordinary Shares (Israel)$6.83----13.4%4321
IOT.MI Seco S.p.A.€4.18----0.1%3639
QMCO Quantum Corporation Common Stock$16.98---0.0%2953
AL2SI.PA 2CRSI S.A.€27.28--73.9x24.1%5448
MUB.DE Mühlbauer Holding AG€43.80€3430% above28.3x13.2%6072

Sector report card

Where DDD ranks against its sector peers on each metric.

Computing percentiles…
  • Business Wire•Sep 8, 2026
    AdaptHealth Appoints Harriss Currie as Chief Financial Officer
  • GlobeNewswire•Aug 27, 2026
    3D Systems Launches Partnership with Savannah River National Laboratory to Advance 3D Printing for Advanced Energy and National Security Applications
  • GlobeNewswire•Aug 13, 2026
    Global 3D Printed Implant Polypropylenes Market Size/Share Worth USD 2.92 Billion by 2035 at a 9.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
4 more press releases · full archive on Investor+.INVESTOR
40 filings
September 2026
Sep 18
Form 4Insider transactionPeriod 2026-09-17
View on SEC →
Sep 18
Form 4Insider transactionPeriod 2026-09-17
View on SEC →
Sep 10
Form 4Insider transactionPeriod 2026-09-08
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR